On October 21, 2020 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, reported that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes (Press release, CryoLife, OCT 21, 2020, View Source [SID1234568762]). On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. A replay of the teleconference will be available November 4 through November 11, 2020 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13712302.

The live webcast and replay can be accessed in the Investor Relations section of the CryoLife website at www.cryolife.com and selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investor Relations section of the CryoLife website.

On October 21, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, reported that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submission of a Pre-IND Meeting request to the FDA on its anti-tumor Drug Candidate CANNABICS RCC-33, the world’s first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer (Press release, Cannabics Pharmaceuticals, OCT 21, 2020, View Source [SID1234568761]). The pre-IND Meeting request with the FDA is expected to be submitted during Q1 of 2021, and subsequently take place in the first half of 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eyal Barad, Cannabics Pharmaceuticals CEO, said: "The company’s decision to move forward with an FDA regulatory path for this specific product is based on a combination of factors including: the promising pre-clinical findings from our licensed in-house Drug Discovery platform in Israel, our proprietary related IP, and our positive market analysis. After many years of R&D and of developing our expertise in anti-cancer drug discovery, we are truly excited to have developed what we believe to be the world’s first cannabinoid-based medicine targeting colorectal cancer."

Prior to filing the request for a pre-IND Meeting, the company plans to carry out a Proof of Concept (POC) study using In-vivo animal models, and a completion of the synopsis of the first in-human phase 1/2a clinical study. All this in conjunction with the development of the CANNABICS RCC-33’s clinical Chemistry Manufacturing & Control (CMC) protocols.

Dr. Eyal Ballan, Cannabics Pharmaceuticals CTO, said "This cooperation has enabled the company to factor in cumulative experience for approaching the FDA on a cannabinoid-based drugs for various specific indications, and we are confident that this collective experience will prove invaluable in the clinical validation process for our CANNABICS RCC-33."

On October 21, 2020 Reference is made to the stock exchange announcement by Nordic Nanovector ASA (the "Company") on 23 and 30 September 2020 where the Company reported the successful completion of a private placement raising gross proceeds of approximately NOK 231 million (the "Private Placement") and that the board of directors would consider to carry out a repair offering of up to 2,285,714 new shares in the Company (the "Repair Offering") (Press release, Nordic Nanovector, OCT 21, 2020, View Source [SID1234568760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has decided not to proceed with the Repair Offering. Since the announcement of completion of the Private Placement, the Company’s shares have traded on the Oslo Stock Exchange, with significant trading volume, at prices close to or below the subscription price in the Private Placement of NOK 17.50. Accordingly, any shareholders wishing to neutralize the dilutive effect of the Private Placement have had the opportunity to purchase shares in the Company in the market, at prices close to or below what would have been the subscription price in a Repair Offering. In light of this, the Company has resolved not to proceed with a Repair Offering that would have resulted in additional costs for the Company.

On October 21, 2020 Amgen (NASDAQ:AMGN) reported that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020 (Press release, Amgen, OCT 21, 2020, View Source [SID1234568758]). The dividend will be paid on December 8, 2020, to all stockholders of record as of the close of business on November 16, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 21, 2020 TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, reported that it will release financial results for the third quarter after market close on Wednesday, November 4, 2020 (Press release, TransMedics, OCT 21, 2020, View Source [SID1234568757]). The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in listening to the conference call may do so by dialing (833) 378-1026 for domestic callers or (236) 712-2500 for international callers, followed by Conference ID: 1716957. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at View Source